Falsely Elevated Blood Glucose Readings with a Point-of-Care Meter Due to a Maltose-Containing Intravenous Immune Globulin Product
MedSun: Newsletter #25, June 2008

Gaines, Ann Reed; Pierce, L. Ross; Bernhardt, Patricia A.
FDA Center for Biologics Evaluation and Research Website

The FDA received a case report of an elderly male diabetic patient that received a 10% maltose-containing intravenous immune globulin product. He later went into a hypoglycemic coma and had irreversible neurological damage secondary to excessive insulin administration. His insulin dosing was guided by falsely elevated blood glucose measurements obtained from a point-of-care glucose meter. Some glucose meter test strips that use glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) methodology may overestimate measurements when blood maltose levels exceed 0.9mmol/L.

Additional Information:

Falsely Elevated Blood Glucose Readings with a Point-of-Care Meter Due to a Maltose-Containing Intravenous Immune Globulin Product. Gaines, Ann Reed; Pierce, L. Ross; Bernhardt, Patricia A.
http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm155099.htm


MedSun Newsletters are available at www.fda.gov/cdrh/medsun